In Vitro Resistance Models for Oncology Discovery

Drug-Resistant Cell Line Screening

Drug resistance remains a major challenge in modern drug development, limiting the durability of targeted therapies and oncology treatments. Cancer cells can develop adaptive mechanisms that reduce treatment sensitivity, including target alteration, pathway reactivation, drug-efflux activation, metabolic rewiring, DNA damage response changes and phenotypic plasticity.

Conventional drug-sensitive cell models may not capture clinically relevant resistance phenotypes, limiting evaluation of therapeutic durability, resistance vulnerabilities and potential combination strategies.

ICE Bioscience provides customized drug-resistant cell-line development and screening services using continuous or stepwise drug exposure and gene-editing-based approaches. These models support mechanism-of-resistance studies, biomarker discovery, vulnerability screening and next-generation therapeutic strategy evaluation.

Core Resistance Models

Model development aligned to therapeutic modality

01 / ADC AND PAYLOAD RESISTANCE

ADC/Payload-driven resistance models ↗ are developed against payload classes such as topoisomerase I inhibitors or tubulin inhibitors to support cross-resistance evaluation and strategy development for ADC programs.

02 / RAS PATHWAY INHIBITORS

Resistant sublines induced by prolonged RAS-inhibitor exposure support pathway-adaptation studies and rational combination exploration.

03 / MOLECULAR CHARACTERIZATION

Optional analysis can include ABCG2 or ABCB1 transporter checks, target and pathway markers, and transcriptomic comparison of parental and resistant lines.

Development Workflow